Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Cemiplimab in MCC and CSCC
NCT04975152Phase 1Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2021
- Primary completion
- Mar 2028
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cemiplimab in Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC), sponsored by Moffitt Cancer Center. Primary endpoint: Adverse Events Related to Study Treatment at 3 years. Started Oct 2021; status: recruiting.
02
Drugs
cemiplimab
03
Conditions
Merkel cell carcinoma (MCC)cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT04975152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04975152.